Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program

Diagnostic Microbiology and Infectious Disease

Volumn 92, Issue 2, 2018, Pages 158-163

  Shortridge, Dee ^a   Pfaller, Michael A ^a,b   Castanheira, Mariana ^a   Flamm, Robert K ^a  

^a JMI Laboratories   (Italy)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Bloodstream isolates; Ceftolozane tazobactam; ESBL; P. aeruginosa; Surveillance

Indexed keywords

AMIKACIN; BETA LACTAMASE CTX M; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTERIACEAE; HOSPITAL PATIENT; IN VITRO STUDY; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; UNITED STATES; BACTEREMIA; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; EPIDEMIOLOGICAL MONITORING; HOSPITAL; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTION;

ANTI-INFECTIVE AGENTS; BACTEREMIA; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EPIDEMIOLOGICAL MONITORING; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TAZOBACTAM; UNITED STATES;

EID: 85048515962     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2018.05.011     Document Type: Article

References (26)

1. Aitken, S.L., Kontoyiannis, D.P., DePombo, A.M., Bhatti, M.M., Tverdek, F.P., Gettys, S.C., et al. Use of ceftolozane/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient. Pediatr Infect Dis J 35 (2016), 1040–1042.
2. Bassetti, M., Righi, E., Carnelutti, A., Bloodstream infections in the intensive care unit. Virulence 7 (2016), 267–279.
3. Bevan, E.R., Jones, A.M., Hawkey, P.M., Global epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemother 72 (2017), 2145–2155.
4. Cabot, G., Bruchmann, S., Mulet, X., Zamorano, L., Moya, B., Juan, C., et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 58 (2014), 3091–3099.
5. Castanheira, M., Farrell, S.E., Deshpande, L.M., Mendes, R.E., Jones, R.N., Prevalence of beta-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY antimicrobial surveillance program (2010). Antimicrob Agents Chemother 57 (2013), 3012–3020.
6. Castanheira, M., Mendes, R.E., Jones, R.N., Sader, H.S., Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-lactamase-producing isolates. Antimicrob Agents Chemother 60 (2016), 4770–4777.
7. Cerceo, E., Deitelzweig, S.B., Sherman, B.M., Amin, A.N., Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist 22 (2016), 412–431.
8. Clinical and Laboratory Standards Institute (CLSI), M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition. 2015, Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute (CLSI), M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. 2017, Clinical and Laboratory Standards Institute, Wayne, PA.
10. EUCAST, Breakpoint tables for interpretation of MIC's and zone diameters. Version 7.1, March 2017. European Committee on Antimicrobial Susceptibility Testing, 2017.
11. Farrell, D.J., Sader, H.S., Flamm, R.K., Jones, R.N., Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). Int J Antimicrob Agents 43 (2014), 533–539.
12. Fraile-Ribot, P.A., Cabot, G., Mulet, X., Perianez, L., Martin-Pena, M.L., Juan, C., et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother 73 (2017), 658–663.
13. Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J.E., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136 (2009), 1237–1248.
14. Livermore, D.M., Mushtaq, S., Meunier, D., Hopkins, K.L., Hill, R., Adkin, R., et al. Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British isles. J Antimicrob Chemother 72 (2017), 2278–2289.
15. Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M.A., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370 (2014), 1198–1208.
16. Patel, U.C., Nicolau, D.P., Sabzwari, R.K., Successful treatment of multi-drug resistant Pseudomonas aeruginosa bacteremia with the recommended renally adjusted ceftolozane/Tazobactam regimen. Infect Dis Ther 5 (2016), 73–79.
17. Popejoy, M.W., Paterson, D.L., Cloutier, D., Huntington, J.A., Miller, B., Bliss, C.A., et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials. J Antimicrob Chemother 72 (2017), 268–272.
18. Sader, H.S., Rhomberg, P.R., Farrell, D.J., Jones, R.N., Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55 (2011), 2390–2394.
19. Seymour, C.W., Gesten, F., Prescott, H.C., Friedrich, M.E., Iwashyna, T.J., Phillips, G.S., et al. Time to treatment and mortality during mandated emergency Care for Sepsis. N Engl J Med 376 (2017), 2235–2244.
20. Sievert, D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan, A., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34 (2013), 1–14.
21. Tangden, T., Giske, C.G., Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 277 (2015), 501–512.
22. Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E.M., Posteraro, B., Fiori, B., et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51 (2007), 1987–1994.
23. Weiner, L.M., Webb, A.K., Limbago, B., Dudeck, M.A., Patel, J., Kallen, A.J., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 37 (2016), 1288–1301.
24. Wyeth Pharmaceuticals, I, Tygacil (tigecycline) Prescribing information. wwwpfizermedicalinformationcom, 2010.
25. ZERBAXA, ZERBAXA® (ceftolozane/tazobactam). 2016, Merck & Co. Inc., Whitehouse Station, NJ.
26. Zilberberg, M.D., Shorr, A.F., Micek, S.T., Vazquez-Guillamet, C., Kollef, M.H., Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care, 18, 2014, 596.